News

News

Two-Year Results CoreValve U.S. Pivotal Trial TCT 2014

In extended follow-up from the CoreValve U.S. Pivotal Trial, the self-expanding transcatheter aortic valve was shown to have low rates of all-cause mortality and major stroke. Findings were...

September 22, 2014 — A first-of-its kind study found that using a cerebral protection device during transcatheter aortic valve replacement (TAVR) can significantly reduce the number and volume of...

September 22, 2014 — According to a new study, while it is common for patients who have migraine to have a patent foramen ovale, a procedure to repair this heart defect does not significantly...

VADs Gain Popularity Artificial Hearts Remain Ideal GlobalData

Robert Littlefield, MSc, GlobalData's senior analyst covering Medical Devices, said: “Since the first implantation of the Jarvik 7 in 1982, artificial heart devices have evolved significantly...

According to a new study, patients receiving six months of dual antiplatelet therapy (DAPT) after receiving a second-generation drug-eluting stent (DES) appeared to have similar outcomes to...

U.S. CoreValve High Risk trial TCT 2014

According to a new study, transcatheter aortic valve replacement (TAVR) provided meaningful clinical benefits relative to surgical aortic valve replacement (SAVR) in high risk patients with...

Study Blood Thinner Heart Attack Patients

The largest prospective longitudinal study of acute myocardial infarction (MI) patients offers unique insight into the use, safety and effectiveness of blood thinners prasugrel and clopidogrel in...

September 19, 2014 — A new study investigating different durations of triple therapy for anticoagulation after drug-eluting stent (DES) implantation demonstrated that six weeks of drug therapy was...

September 19, 2014 — According to a new study, peritoneal hypothermia is feasible for patients who have suffered ST-segment elevation myocardial infarction (STEMI). However, the procedure was...

PARTNER I Trial TCT 2014 TAVR Heart Valve Repair

New data from a landmark clinical trial found that after five years, transcatheter aortic valve replacement (TAVR) demonstrated a persistent mortality benefit, improved functional status, and...

A new study found that fractional flow reserve (FFR)-guided provisional side branch (SB) stenting of true coronary bifurcation lesions yields similar outcomes to the current standard of care. The...

September 17, 2014 — A new clinical trial found that vascular closure devices (VCDs) are non-inferior to manual compression in patients undergoing transfemoral coronary angiography. The findings...

September 17, 2014 — GE Healthcare announced it has installed its Cath Lab Efficiency Manager at Saint Luke’s Mid America Heart Institute in Kansas City, Mo. The solution is a new analytical tool...

Unexpected trips to the hospital are inconvenient and worrisome for anyone, but for congestive heart failure sufferers, they can be all too frequent.

BioControl Medical Enrollment INOVATE-HF Study CardioFit System Heart Failure

BioControl Medical announced that it has reached an important clinical trial milestone, reaching 480 randomized subjects — or 70 percent — of the planned 650 subjects with congestive...

September 16, 2014 — A quarter of adults in the United States have two or more chronic medical conditions, as do more than two-thirds of seniors, yet there are few clinical practice guidelines for...

September 16, 2014 — Advanced Accelerator Applications (AAA), an international specialist in molecular nuclear medicine, announced this week it has entered into an agreement with GE Healthcare in...

Tryton Medical First U.S. Patient Extended Access Registry

Tryton Medical Inc. announced that the first patient in the United States has been enrolled in the Extended Access Registry, a single arm study of its Tryton Side Branch Stent. 

St. Jude Medical Portico TAVR System Minneapolis Heart Institute Implant Trial

The Minneapolis Heart Institute Foundation (MHIF) announced its first implant of the Portico Re-sheathable Transcatheter Aortic Valve System, developed by St. Jude Medical. 

September 15, 2014 — A new gene-directed drug being tested through a research study called GENETIC-AF may improve care, quality of life and survival in patients with heart failure and atrial...